Trevi Therapeutics completed a $162 million stock offering, extending its cash runway into 2030 to support ongoing development of Haduvio for chronic cough related to IPF, non-IPF ILD, and refractory chronic cough. The company plans to initiate multiple clinical trials in 2026, including Phase 3 trials for IPF-related chronic cough and Phase 2b trials for RCC and non-IPF ILD-related cough. With recent FDA alignment and a new European patent, Trevi is positioned to advance toward potential FDA approval. Financially, the company reported a net loss of $13.2 million for Q1 2026, with increased R&D and administrative expenses reflecting clinical progress.
DelveInsight's 2026 report reveals a robust pipeline with 75+ drugs under development for Duchenne muscular dystrophy (DMD), involving 70+ companies. Key therapies focus on gene and mutation-targeted approaches to slow disease progression, addressing...
Eramet has appointed Simon Henochsberg as its new Group Chief Financial Officer and member of the Executive Committee, effective May 26, 2026. Henochsberg, who previously served as Vice President of Group Strategy and co-Chief Financial Officer, brin...
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
